Domov › Kolorektalni rak › Texas › San Antonio
Klinične študije za Kolorektalni rak v San Antonio, TX
46 študij za Kolorektalni rak išče udeležence na lokacijah v San Antonio in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Vključevanje udeležencevFaza 3
- Texas Oncology - San Antonio, San Antonio
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Vključevanje udeležencevFaza 3
- Texas Oncology - San Antonio, San Antonio
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- START San Antonio, San Antonio
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Vključevanje udeležencevFaza 2/3
- Texas Oncology - San Antonio, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Vključevanje udeležencevFaza 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Vključevanje udeležencevFaza 1/2
- START San Antonio, San Antonio
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Vključevanje udeležencevFaza 3
- Texas Oncology- San Antonio, San Antonio
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Vključevanje udeležencevFaza 2
- Mays Cancer Center at University of Texas Health at San Antonio, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Vključevanje udeležencevFaza 1
- NEXT San Antonio, San Antonio
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- UT Health Mays Cancer Center, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Clinical Trial Site, San Antonio
IDOV-Immune for Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics, San Antonio
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Vključevanje udeležencevFaza 1/2
- GSK Investigational Site, San Antonio
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Vključevanje udeležencevFaza 1/2
- NEXT Oncology, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Texas Oncology - San Antonio, San Antonio
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Next Oncology, San Antonio
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- START San Antonio, San Antonio
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- START San Antonio, LLC., San Antonio
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- New Experimental Therapeutics of San Antonio LLC, San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Vključevanje udeležencevFaza 1/2
- Next Oncology-Oncology, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Vključevanje udeležencevFaza 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Texas LLC - San Antonio, San Antonio
- Start San Antonio, LLC, San Antonio
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Vključevanje udeležencevFaza 1
- Context Investigational Site, San Antonio
- Context Investigational Site, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Vključevanje udeležencevFaza 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Vključevanje udeležencevFaza 1
- START, San Antonio
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Vključevanje udeležencevFaza 1/2
- Next Oncology, San Antonio
A Study of MGC028 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Vključevanje udeležencevFaza 1/2
- NEXT Oncology, San Antonio
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Vključevanje udeležencevFaza 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- START San Antonio, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Vključevanje udeležencevFaza 1/2
- START San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Vključevanje udeležencevFaza 1/2
- Next Oncology, San Antonio, San Antonio
Študije za Kolorektalni rak v drugih mestih
- Houston, TX102 študij
- New York City, NY78 študij
- Nashville, TN69 študij
- Boston, MA63 študij
- Los Angeles, CA59 študij
- Arlington, VA52 študij
- St. Louis, MO50 študij
- Philadelphia, PA44 študij
- Grand Rapids, MI40 študij
- Baldwin Park, CA37 študij
- Chicago, IL34 študij
- Tampa, FL34 študij
Druge študije v San Antonio
- Nemalicelični pljučni rak59 študij
- Rak dojke47 študij
- Metastatski rak44 študij
- Rak (vse vrste)41 študij
- Debelost40 študij
- Sladkorna bolezen tipa 237 študij
- Prekomerna telesna teža34 študij
- Rak jajčnikov31 študij
- Rak trebušne slinavke31 študij
- Rak prostate28 študij
- Rak endometrija27 študij
- Rak pljuč26 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.